title: Propranolol for treatment of ulcerated infantile hemangiomas.
abstract: BACKGROUND
  Ulcerated infantile hemangiomas (IH) are a therapeutic challenge. Propranolol, a nonselective beta-blocker, was recently introduced as a novel treatment for IH.
  
  
  OBJECTIVE
  To evaluate our experience of propranolol in the management of ulcerated IH.
  
  
  METHODS
  A national, multicenter, retrospective, observational study was conducted. Data were collected from the medical charts of patients treated from 2008 to 2009 and supplemented by information obtained from parents during targeted telephone interviews.
  
  
  RESULTS
  Thirty-three infants with propranolol-treated ulcerated IH were included. The average time to complete ulceration healing was 4.3 weeks in 30 of 33 patients and was significantly faster for head-and-neck locations (P = .0354). The mean time to complete pain control was 14.5 days. Parents rated treatment as very effective for 27 of 31 patients and very well tolerated for 29 of 31 cases.
  
  
  CONCLUSIONS
  This was a retrospective uncontrolled study.
  
  
  CONCLUSIONS
  Propranolol appears to be an effective and well-tolerated treatment for ulcerated IH.
authors.affiliation: Department of Dermatology, Hôtel-Dieu, 44093 Nantes, France.
authors.forename: Mélanie
authors.initials: M
authors.lastname: Saint-Jean
authors.forename: Christine
authors.initials: C
authors.lastname: Léauté-Labrèze
authors.forename: Juliette
authors.initials: J
authors.lastname: Mazereeuw-Hautier
authors.forename: Nathalie
authors.initials: N
authors.lastname: Bodak
authors.forename: Dominique
authors.initials: D
authors.lastname: Hamel-Teillac
authors.forename: Ingrid
authors.initials: I
authors.lastname: Kupfer-Bessaguet
authors.forename: Jean-Philippe
authors.initials: JP
authors.lastname: Lacour
authors.forename: Michaël
authors.initials: M
authors.lastname: Naouri
authors.forename: Pierre
authors.initials: P
authors.lastname: Vabres
authors.forename: Smail
authors.initials: S
authors.lastname: Hadj-Rabia
authors.forename: Jean-Michel
authors.initials: JM
authors.lastname: Nguyen
authors.forename: Jean-François
authors.initials: JF
authors.lastname: Stalder
authors.forename: Sébastien
authors.initials: S
authors.lastname: Barbarot
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D005260:Female; D006258:Head and Neck Neoplasms / Q000188:drug therapy; D006391:Hemangioma / Q000150:complications / Q000188:drug therapy* / Q000473:pathology*; D006801:Humans; D008297:Male; D011433:Propranolol / Q000008:administration & dosage / Q000627:therapeutic use*; D012189:Retrospective Studies; D012878:Skin Neoplasms / Q000188:drug therapy*; D012883:Skin Ulcer / Q000188:drug therapy / Q000209:etiology; D016896:Treatment Outcome; D014945:Wound Healing / Q000187:drug effects
chemical_list: D000319:Adrenergic beta-Antagonists; D011433:Propranolol